Surgery – Means for introducing or removing material from body for... – Infrared – visible light – ultraviolet – x-ray or electrical...
Reexamination Certificate
2008-01-29
2008-01-29
Steadman, David J. (Department: 1656)
Surgery
Means for introducing or removing material from body for...
Infrared, visible light, ultraviolet, x-ray or electrical...
C514S002600, C530S324000
Reexamination Certificate
active
07324846
ABSTRACT:
Methods of modifying polypeptide drugs in order to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr) and/or asparagine (Asn) residue(s). The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. Compositions containing the modified polypeptide, which are useful for transdermal electrotransport delivery, are also provided.
REFERENCES:
patent: 4250878 (1981-02-01), Jacobsen et al.
patent: 4383529 (1983-05-01), Webster
patent: 4431739 (1984-02-01), Riggs
patent: 4528190 (1985-07-01), Vale et al.
patent: 4628043 (1986-12-01), Spiess et al.
patent: 4631211 (1986-12-01), Houghten
patent: 4722726 (1988-02-01), Sanderson et al.
patent: 5013653 (1991-05-01), Huston et al.
patent: 5250022 (1993-10-01), Chien et al.
patent: 5250023 (1993-10-01), Lee et al.
patent: 5494679 (1996-02-01), Sage, Jr. et al.
patent: 0 278 473 (1988-08-01), None
patent: 0 643 981 (1994-09-01), None
patent: 0 667 355 (1995-02-01), None
patent: WO 92/12999 (1992-08-01), None
patent: WO 93/25197 (1993-12-01), None
patent: WO 95/11988 (1995-05-01), None
Steadman et al. (1998) Biochemstry 37:7089-7095.
“Introduction to Protein Structure,” Branden and Tooze, Garland Publishing, Inc., New York, 1991, p. 247.
Colman et al. Res Immun 145:33-36, 1996.
Abaza et al. J Protein Chem 11:433-444, 1992.
Hoppe-Seyler's Z. Physiol Chem (1979) 360:1619-1632.
Voet et al., “Biochemistry,” John Wiley and Sons, New York, 1990, pp. 61-64.
Kumar et al. (1990) Proc Intern Symp Control Rel Bioact Mater 17:435-436, Controlled Release Society, Inc.
Obermuller et al. (2002) J Cell Sci 115:185-194.
Burnette, et al.,J. Pharm. Sci., (1986) vol. 75, 738.
Chien, et al.,J. Pharm. Sci., (1988) vol. 78, 376.
Maulding, et al., U.S. Statutory Invention Registration No. H1160, 1993.
Nozaki, et al.,J. Biol. Chem., (1971) vol. 246, 2211-2217.
Merrifield, et al.,Biochemistry, (1981) vol. 21, 5020.
Bodanszky, “Principles of Peptide Synthesis,” (1984) Akad.-Verlag.
Stewart, et al., “Solid Phase Peptide Synthesis,” (1969) Freeman.
Houghten,Proc. Natl. Acad. Sci. USA, (1985) vol. 82, 5131-5135.
Houghten, et al.,Peptide Chemistry, (1987) 295-298.
Beaucage, et al.,Tetrahedron Lett., (1981) vol. 22, 1859-1862.
Matteneci, et al.,J. Am. Chem. Soc., (1981) vol. 103, 3185-3191.
Green, et al., “Iontophoretic Delivery of a Series of Tripeptides Across the Skin in Vitro,”Pharmaceutical Research, (1991) vol. 8 No. 9, 1121-1127.
Markussen, et al., “Soluble, Prolonged-Acting Insulin Derivatives. III. Degree of Protraction, Crystallizability, and Chemical Stability of Insulins Substituted in Positions A21, B13, B23, B27, and B30,”Protein Engineering, (Jul. 1988) vol. 2 No. 2, 157-166.
Lohse, et al., “Three Genetic Variants of Human Plasma Apolipoprotein A-IV”J. Biol. Chem. (Jul. 25, 1991) vol. 266 No. 21, 13513-13518.
Green, et al., “Transdermal iontophoresis of amino acids and peptides in vitro,”J. of Controlled Release, (1992) 21:187-190.
Reichardt, et al., “Molecular characterization of two galactosemia mutations: correlation of mutations with highly conserved domains in galactose-1-phosphate uridyl transferase,”Am. J. Hum. Genet., (1991) vol. 49(4):860-7.
Nishimura, et al., “Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X,”J. Biol. Chem., (1993) 24041-6.
Levine, B. et a;., “Molecular Analysis of Neurovirulent Strains of Sindbis Virus that Evolve during Persistent Infection ofscidMice”,Journal of Virology, 1993, (67)11, 6872-6875.
Alza Corp.
Steadman David J.
LandOfFree
Method of enchancing electrontransport polypeptide flux by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enchancing electrontransport polypeptide flux by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enchancing electrontransport polypeptide flux by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764021